Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Kobe, HyogoFounded 19683,011 employeesWebsite
A global leader in clinical testing instruments and reagents, holding the top world market share in the field of hematology (blood cell counting).
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| EMEA Regional Management | 30% | ¥152.1B | ¥9.9B | 6.5% |
| Americas Regional Management | 26% | ¥130.5B | ¥8.5B | 6.5% |
| China Regional Management | 18% | ¥89.3B | ¥9.3B | 10.5% |
| Headquarters and Japan | 18% | ¥87.6B | ¥17.8B | 20.3% |
| Asia Pacific Regional Management | 8% | ¥40.6B | ¥3.7B | 9.1% |
Close (Oct 30, 2026)
¥1,941.5+12.0% (1Y)
Sysmex +12.0% over 1Y, 5.8pt above the industry average (9 companies, +6.2%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥500.0B | ¥51.8B | ¥35.5B | ¥707.5B | -1.7% |
| 2025FY | ¥508.6B | ¥87.6B | ¥53.7B | ¥665.3B | +10.2% |
| 2024FY | ¥461.5B | ¥78.4B | ¥49.6B | ¥618.9B | +12.4% |
| 2023FY | ¥410.5B | ¥73.7B | ¥45.8B | ¥531.1B | +12.8% |
| 2022FY | ¥363.8B | ¥67.4B | ¥44.1B | ¥483.7B | +19.2% |
| 2021FY | ¥305.1B | ¥50.0B | ¥31.9B | ¥424.9B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
